Rani Therapeutics Holdings Inc. is a pioneering biotechnology company that is revolutionizing the delivery of injectable therapies through its proprietary RaniPill™ technology, enabling oral administration of biologics. This innovative platform addresses critical patient adherence issues and caters to the increasing demand for non-invasive treatment options. With a diverse and promising pipeline targeting various therapeutic areas, Rani Therapeutics is poised to redefine drug delivery methodologies. The company's strong emphasis on research and development, combined with strategic partnerships, positions it for substantial growth and meaningful advancements in the pharmaceutical industry.
| Revenue (TTM) | $3.17M |
| Gross Profit (TTM) | $3.17M |
| EBITDA | $-33.83M |
| Operating Margin | -488.20% |
| Return on Equity | -240.00% |
| Return on Assets | -57.00% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.28 |
| Price-to-Book | 3.07 |
| Price-to-Sales (TTM) | 30.77 |
| EV/Revenue | 15.05 |
| EV/EBITDA | -1.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 893.00% |
| Shares Outstanding | $112.39M |
| Float | $69.15M |
| % Insiders | 4.99% |
| % Institutions | 43.87% |
Volatility is currently expanding
SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Nicholas Maestas as Chief Financial Officer, effective immediately.
SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement led by a sovereign wealth fund, along with other new and existing healthcare-focused funds for the purchase and sale of 12,476,637 shares of Rani Therapeutics' Class A common stock at a purchase price of $1.07 per share and pre-funded warrants to purchase 6,214,953 shares of Class A common stock at a purchase price of $1.0699 per pre-funded warrant in a registered direct offering priced at-the-market under Nasdaq rules.
- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen –
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's management team will participate in the upcoming H.C.
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Høiland as Head of Strategy.
